Summary of Tirzepatide SURPASS Ph3 Event
Today, Lilly hosted a webcast presenting an overview of the Ph3 tirzepatide SURPASS program. Of note, Lilly highlighted that topline data from SURPASS-1 is anticipated in mid-December 2020 with US/EU filing in late 2021/early 2022. Below, FENIX provides highlights from the call as well as insights into the incretin dynamics in the T2DM space.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.